Onko-Gene

Critical literature watch in the molecular oncology of solid tumors

FREN

Clinical · Molecular biology · Bioinfo & AI

Molecular subtyping and POLE mutation spectrum in endometrial carcinoma

Summary

This study characterized the molecular subtypes and the spectrum of POLE gene mutations in a South Indian cohort of endometrial carcinoma patients. Using the ProMisE classification, researchers identified four molecular subgroups: POLE ultra-mutated, MMR-deficient, p53-abnormal, and no specific molecular profile (NSMP). POLE gene sequencing revealed known variants like V411L, as well as several non-hotspot variants, six of which were unique to this cohort and four predicted to be oncogenic. p53-abnormal tumors exhibited a more aggressive phenotype and increased chemotherapy use. The integration of molecular profiling with histopathology is deemed crucial for enhancing endometrial carcinoma classification and prognostic assessment.

Critical appraisal

Clinical. This study reinforces the importance of molecular subtyping in endometrial carcinoma for improved prognostic and therapeutic stratification. The ProMisE classification, combining IHC for MMR and p53 proteins with POLE sequencing, identifies subgroups with distinct clinical implications. Notably, p53-abnormal tumors are associated with an aggressive phenotype, advanced stage, and more frequent chemotherapy use (55.6%), suggesting the need for more intensive management. These findings could justify clinical trials aimed at tailoring therapeutic strategies based on molecular subtype, with a potential clinical impact in the medium term (3-5 years) to refine treatment guidelines.

Molecular biology. The research identified a spectrum of POLE exonuclease domain mutations, including the recurrent p.V411L variant and ten non-hotspot variants, six of which are unique to the studied cohort (p.T466I, p.V460M, p.L306P, p.P441S, p.T290I, p.E321K). The use of Sanger sequencing for POLE and immunohistochemistry for MMR and p53 proteins represents a robust approach for molecular profiling. The discovery of unique variants and the prediction of their oncogenic potential (p.V460M, p.P441S, p.T290I, p.E321K) using in silico tools are significant advancements. These discoveries could form the basis for future predictive or prognostic biomarkers, requiring further functional and clinical validation, potentially through targeted NGS panels for broader and faster detection.

Bioinfo & AI. The study utilized in silico tools to evaluate the pathogenicity of POLE gene variants, which is a standard yet critical application in clinical bioinformatics. This approach allows for the classification of identified variants, particularly non-hotspot and unique variants, based on their oncogenic potential. While specific tool details are not provided, their use is essential for variant interpretation and for prioritizing those requiring functional investigation. Clinically, integrating such tools into genomic analysis pipelines could enhance the efficiency of variant interpretation and decision-making for molecular tumor boards.

The summary and the appraisal were written by a language model from the title and abstract of the original article. A curator decided to publish it. Methodology